CO6612199A2 - Pèptidos tau antigènicos y usos de los mismos - Google Patents

Pèptidos tau antigènicos y usos de los mismos

Info

Publication number
CO6612199A2
CO6612199A2 CO12026764A CO12026764A CO6612199A2 CO 6612199 A2 CO6612199 A2 CO 6612199A2 CO 12026764 A CO12026764 A CO 12026764A CO 12026764 A CO12026764 A CO 12026764A CO 6612199 A2 CO6612199 A2 CO 6612199A2
Authority
CO
Colombia
Prior art keywords
tau peptides
antigenic tau
compositions
immunogens
antigenic
Prior art date
Application number
CO12026764A
Other languages
English (en)
Inventor
George Joseph Smith
Kenneth Nelson Wills
Jeff Xianchao Zhu
Original Assignee
George Joseph Smith
Kenneth Nelson Wills
Jeff Xianchao Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Joseph Smith, Kenneth Nelson Wills, Jeff Xianchao Zhu filed Critical George Joseph Smith
Publication of CO6612199A2 publication Critical patent/CO6612199A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se refiere a nuevos inmunógenos y composiciones que comprenden un péptido tau antigénico, preferentemente unido a un vehículo inmunogénico para su uso en el tratamiento de trastornos neurológicos relacionados con tau. La divulgación se refiere además a procedimientos para la producción de estos inmunógenos y composiciones y a su uso en medicina.
CO12026764A 2009-07-30 2012-02-15 Pèptidos tau antigènicos y usos de los mismos CO6612199A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22986009P 2009-07-30 2009-07-30

Publications (1)

Publication Number Publication Date
CO6612199A2 true CO6612199A2 (es) 2013-02-01

Family

ID=42941871

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12026764A CO6612199A2 (es) 2009-07-30 2012-02-15 Pèptidos tau antigènicos y usos de los mismos

Country Status (17)

Country Link
US (1) US20110177109A1 (es)
EP (1) EP2459214A1 (es)
JP (1) JP2013500326A (es)
KR (2) KR20130127547A (es)
CN (1) CN102596236B (es)
AR (1) AR078085A1 (es)
AU (1) AU2010277254B2 (es)
CA (1) CA2768346A1 (es)
CO (1) CO6612199A2 (es)
IN (1) IN2012DN00446A (es)
MX (1) MX2012001194A (es)
NZ (2) NZ598356A (es)
PE (1) PE20120817A1 (es)
RU (2) RU2518291C2 (es)
SG (1) SG177637A1 (es)
TW (2) TW201436804A (es)
WO (1) WO2011013034A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
MX2011006088A (es) 2008-12-09 2011-06-21 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores.
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EP3329932A1 (en) * 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
EP2764022B9 (en) 2011-10-07 2017-02-22 AC Immune S.A. Phosphospecific antibodies recognising tau
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
CA2877397A1 (en) * 2012-07-03 2014-01-09 Washington University Antibodies to tau
MY176838A (en) 2012-08-16 2020-08-24 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2970452A2 (en) 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
WO2015017280A1 (en) * 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
US10400018B2 (en) 2014-02-14 2019-09-03 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3166688B1 (en) 2014-07-08 2024-08-21 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
US20180050097A1 (en) * 2015-03-25 2018-02-22 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
PE20180499A1 (es) 2015-07-06 2018-03-09 Ucb Biopharma Sprl Anticuerpos de union a tau
JP6913078B2 (ja) 2015-08-13 2021-08-04 ニューヨーク・ユニバーシティ タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
EP3519425B1 (en) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
CR20240219A (es) * 2017-10-25 2024-07-09 Ac Immune Sa COMPOSICIONES DE PÉPTIDOS TAU FOSFORILADOS Y SUS USOS (DIVISIONAL Exp. 2020-0219)
US11773148B2 (en) * 2017-10-27 2023-10-03 United Neuroscience Tau peptide immunogen constructs
CN109870581B (zh) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
CN108314737B (zh) * 2018-01-25 2021-03-16 中国科学院过程工程研究所 一种重组蛋白及其制备方法和应用
CN110548135B (zh) * 2018-05-31 2023-06-06 长春百克生物科技股份公司 磷酸化多肽抗原疫苗及其制备方法和应用
US20230051538A1 (en) * 2018-10-07 2023-02-16 The University Of British Columbia Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
CA3129252A1 (en) 2019-02-08 2020-08-13 Ac Immune S.A. Method of safe administration of phosphorylated tau peptide vaccine
WO2020186091A1 (en) * 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
AU2020262899A1 (en) 2019-04-24 2021-11-18 Ac Immune S.A. Heterologous administration of tau vaccines
GB2585252A (en) * 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
WO2022054795A1 (ja) * 2020-09-08 2022-03-17 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
JP2024534976A (ja) * 2021-09-08 2024-09-26 ジョイント・ストック・カンパニー “バイオキャド” Ｍｈｃタンパク質に基づくヘテロ二量体を含む二重特異性抗体
WO2023056369A1 (en) * 2021-09-29 2023-04-06 Janssen Pharmaceuticals, Inc. Method of safe administration of tau phosphopeptide conjugate
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
AU568067B2 (en) 1981-10-23 1987-12-17 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3525624A1 (de) 1985-07-18 1987-01-22 Celamerck Gmbh & Co Kg Insektizid wirksames mittel zur bekaempfung von textilschaedlingen
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
EP0618968B1 (en) * 1991-12-06 1999-10-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
PL178578B1 (pl) 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
TR200002338T2 (tr) 1998-02-12 2002-06-21 Immune Complex Corporation Stratejik olarak yenilenmiş hepatit B çekirdek proteinler.
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
JP2002511423A (ja) 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
IL142980A0 (en) 1998-11-05 2002-04-21 Powderject Vaccines Inc Nucleic acid constructs for genetic immunization
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
KR100808313B1 (ko) 2000-04-07 2008-02-27 유니버시티 오브 리즈 이노베이션즈 리미티드 비형 간염 코어 항원 융합 단백질
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
JP2004500868A (ja) 2000-06-22 2004-01-15 セルテック　ファーマスーティカルズ　リミテッド Ｂ型肝炎コア抗原の修飾
AU2001269272A1 (en) 2000-07-15 2002-01-30 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
WO2003102165A2 (en) 2002-02-21 2003-12-11 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
BR0312935A (pt) 2002-07-17 2005-06-21 Cytos Biotechnology Ag Partìcula semelhante a vìrus, muteìna, vetores para produzir a referida partìcula e proteìna recombinante, composição, processo para produção de fileira ordena e repetitva de antìgeno, molécula de ácido nucléico, célula hospedeira, método para produção da referida partìcula e uso da composição de vacina
NZ537688A (en) * 2002-07-19 2007-01-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays for treating and/or attenuating Alzheimer's disease
KR100991679B1 (ko) 2002-12-10 2010-11-04 셀덱스 테라퓨틱스 리미티드 안정화 면역원성 ＨＢｃ 키메라 입자
SG182163A1 (en) * 2003-12-17 2012-07-30 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
JP2008506683A (ja) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
NZ553244A (en) 2004-07-18 2009-10-30 Csl Ltd Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
CA2583017A1 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
ATE473758T1 (de) * 2006-04-13 2010-07-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Her-2/neu multipeptidimpfstoff
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
EP3329932A1 (en) * 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
FR3058624B1 (fr) 2016-11-15 2018-12-07 L'oreal Brosse pour l'application d'un produit sur les cils et/ou les sourcils

Also Published As

Publication number Publication date
NZ598356A (en) 2014-06-27
AR078085A1 (es) 2011-10-12
KR20120049900A (ko) 2012-05-17
WO2011013034A1 (en) 2011-02-03
JP2013500326A (ja) 2013-01-07
RU2518291C2 (ru) 2014-06-10
MX2012001194A (es) 2012-03-07
RU2014112002A (ru) 2015-10-10
RU2012102701A (ru) 2013-09-10
NZ618391A (en) 2015-07-31
AU2010277254A1 (en) 2012-02-09
IN2012DN00446A (es) 2015-05-15
TWI461209B (zh) 2014-11-21
CN102596236A (zh) 2012-07-18
AU2010277254B2 (en) 2015-05-07
SG177637A1 (en) 2012-03-29
EP2459214A1 (en) 2012-06-06
PE20120817A1 (es) 2012-07-07
CN102596236B (zh) 2015-06-24
CA2768346A1 (en) 2011-02-03
TW201436804A (zh) 2014-10-01
TW201106968A (en) 2011-03-01
KR20130127547A (ko) 2013-11-22
US20110177109A1 (en) 2011-07-21
WO2011013034A4 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CO6612199A2 (es) Pèptidos tau antigènicos y usos de los mismos
CO6501190A2 (es) Vacuna de pcsk9
CO6561830A2 (es) Vacuna de péptido ch3 de ige
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
BR112013013167A8 (pt) inibidores de bromodomínio e usos dos mesmos
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
BR112014022562A8 (pt) Formulação de rna para imunoterapia
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
AR083561A1 (es) Preparacion de una construccion antigenica
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
UY32451A (es) Moléculas de anticuerpo con especifidad por el ox40 humano
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
CL2016002245A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
UY33017A (es) Tratamiento para trastornos gastrointestinales
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
UY31645A1 (es) Nuevas imidazolidinas fenil-sustituidas, procedimiento para su preparación, medicamentos que conprenden dichos compuestos y su uso.
CO6511204A2 (es) Derivados de isoxazolidina
CL2012002954A1 (es) Compuestos derivados de heterobiaril-ciclohexil-tetraazabenzo[e]azules sustituidos, modulares del receptor de vasopresina v1a; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o el tratamient5o de la dismenorrea, disfuncion sexual masculina o femenina, ansiedad, hipertension, entre otros.
CL2011000405A1 (es) Compuestos derivados de n-sulfonamido pirazolil policiclico; inhibidores de la liberacion y sintesis de peptidos beta-amiloides y y-secretasa; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades alzheimer, parkinson, sindrome de down, entre otras.
CL2017001588A1 (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos
ECSP12012102A (es) Proceso para producir un extracto de alérgenos
CR20130065A (es) Composiciones de anticuertpo anti-vegfr-3
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria